Novogen Profit Margin 2006-2020 | KZIA
Current and historical gross margin, operating margin and net profit margin for Novogen (KZIA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Novogen net profit margin as of December 31, 2020 is 0%.
|Novogen Annual Profit Margins
|Novogen Quarterly Profit Margins
||Medical - Biomedical and Genetics
Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, is based in Sydney, Australia.